Whitehawk Therapeutics, Inc. (WHWK) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
WHWK currently has 49.5M outstanding shares. with significant dilution risk as 201M authorized shares could dilute existing holders by 405.8%. The company has significantly diluted shareholders by 78.79% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 29, 2026 |
S-3 filing: The company is registering 22,321,887 shares of common stock for resale by selling stockholders, consisting of 4,330,866 outstanding shares and 17,991,021 shares issuable upon exercise of pre-funded warrants. |
49M | 200M |
| May 07, 2026 |
10-Q filing | 49.5M shares outstanding |
49M | 180M |
| Mar 12, 2026 |
10-K filing | 47.2M shares outstanding |
47M | 180M |
| Nov 06, 2025 |
10-Q filing | 47.1M shares outstanding |
47M | 180M |
| Aug 07, 2025 |
10-Q filing | 47.1M shares outstanding |
47M | 180M |
| May 08, 2025 |
10-Q filing | 47.1M shares outstanding |
47M | 180M |
| Mar 31, 2025 |
S-3 filing: This S-3 filing relates to the offer and resale from time to time of up to 41,668,500 shares of common stock by the selling stockholders. |
47M | 180M |
| Mar 28, 2025 |
10-K filing | 46.8M shares outstanding |
47M | 140M |
| Nov 06, 2024 |
10-Q filing | 27.0M shares outstanding |
27M | 160M |
| Aug 07, 2024 |
10-Q filing | 27.0M shares outstanding |
27M | 160M |
| May 08, 2024 |
10-Q filing | 27.0M shares outstanding |
27M | 160M |
| Mar 13, 2024 |
10-K filing | 26.9M shares outstanding |
27M | 160M |
| Feb 12, 2024 |
S-3 filing: Aadi Bioscience, Inc. files an S-3 to offer common stock, preferred stock, and debt securities up to an aggregate offering price of $150,000,000. |
25M | 160M |
| Nov 08, 2023 |
10-Q filing | 26.9M shares outstanding |
27M | 160M |
| Aug 09, 2023 |
10-Q filing | 26.9M shares outstanding |
27M | 160M |
| May 10, 2023 |
10-Q filing | 26.9M shares outstanding |
27M | 160M |
| Mar 29, 2023 |
10-K filing | 22.5M shares outstanding |
23M | 160M |
| Nov 09, 2022 |
10-Q filing | 24.4M shares outstanding |
24M | 160M |
| Oct 26, 2022 |
S-3 filing: Aadi Bioscience, Inc. is offering 5,800,019 shares of common stock for resale by selling stockholders. |
21M | 170M |
| Aug 10, 2022 |
10-Q filing | 21.0M shares outstanding |
21M | 160M |
| May 12, 2022 |
10-Q filing | 20.9M shares outstanding |
21M | 160M |
| Mar 17, 2022 |
10-K filing | 20.9M shares outstanding |
21M | 160M |
| Nov 10, 2021 |
10-Q filing | 20.9M shares outstanding |
21M | 160M |
| Sep 24, 2021 |
S-3 filing: This S-3 filing relates to the offer and resale of up to 17,629,522 shares of common stock by selling stockholders. |
47M | 130M |
| Aug 11, 2021 |
10-Q filing | 47.4M shares outstanding |
47M | 120M |
| May 17, 2021 |
10-Q filing | 47.4M shares outstanding |
47M | 120M |
| Apr 08, 2021 |
S-3 filing: The filing is for a shelf offering of up to $150,000,000 in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units. |
47M | 120M |
| Mar 11, 2021 |
10-K filing | 47.3M shares outstanding |
47M | 0 |
| Nov 10, 2020 |
10-Q filing | 47.1M shares outstanding |
47M | 0 |
| Aug 12, 2020 |
10-Q filing | 40.9M shares outstanding |
41M | 0 |
| May 07, 2020 |
10-Q filing | 40.6M shares outstanding |
41M | 0 |
| Mar 16, 2020 |
10-K filing | 40.6M shares outstanding |
41M | 0 |